Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart

@article{Farr2015HumanPO,
  title={Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 4h apart Human pharmacology of MDMA after repeated doses taken 4h apart},
  author={Mag{\'i} Farr{\'e} and A Tomillero and Clara P{\'e}rez-Ma{\~n}{\'a} and Samanta Yubero and Esther Papaseit and Pere Nolasc Roset and Mitona Pujadas and Marta Torrens and Jordi Cam{\'i} and Rafael de la Torre},
  journal={European Neuropsychopharmacology},
  year={2015},
  volume={25},
  pages={1637-1649}
}
3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) is a popular psychostimulant, frequently associated with multiple administrations over a short period of time. Repeated administration of MDMA in experimental settings induces tolerance and metabolic inhibition. The aim is to determine the acute pharmacological effects and pharmacokinetics resulting from two consecutive 100mg doses of MDMA separated by 4h. Ten male volunteers participated in a randomized, double-blind, crossover, placebo… Expand
Safety pharmacology of acute MDMA administration in healthy subjects
TLDR
MDMA administration was overall safe in physically and psychiatrically healthy subjects and in a medical setting, however, the risks of MDMA are likely higher in patients with cardiovascular disease and remain to be investigated in Patients with psychiatric disorders. Expand
Human Pharmacology of Mephedrone in Comparison with MDMA
TLDR
Mephedrone elicited stimulant-like effects, euphoria, and well-being, and induced mild changes in perceptions with similar ratings to those observed after MDMA administration although effects peaked earlier and were shorter in duration. Expand
MDMA interactions with pharmaceuticals and drugs of abuse
TLDR
This article provides an overview of the MDMA-DIs with pharmaceuticals and drugs of abuse and points out the relevance of MDMA-DI’s when MDMA is co-administered with Pharmaceuticals that are metabolized by the CYP2D6 due to MDMA inhibitory action. Expand
Chiral Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine and its Phase I and II Metabolites following Controlled Administration to Humans
TLDR
These are the first data on chiral pharmacokinetics of MDMA phase II metabolites in human plasma in vivo after controlled administration. Expand
Key interindividual determinants in MDMA pharmacodynamics
TLDR
The aim of this review is to present the main interindividual determinants in MDMA pharmacodynamics, with special emphasis on sex-gender, race-ethnicity, genetic differences, interactions, and MDMA acute toxicity, as well as possible therapeutic use. Expand
Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans
TLDR
Although changes in stereoselectivity based on CYP2D6 activity were observed, these likely have low clinical relevance and might aid further interpretations of toxicity based on CyP1D6-dependent MDMA metabolism. Expand
Acute Effects of 2C-E in Humans: An Observational Study
2,5-Dimethoxy-4-ethylphenethylamine (2C-E) is psychedelic phenylethylamine, with a chemical structure similar to mescaline, used as new psychoactive substance (NPS). It inhibits norepinephrine andExpand
Mephedrone and Alcohol Interactions in Humans
TLDR
The mephedrone and alcohol combination produced an increase in the cardiovascular effects of mep hedrone and induced a more intense feeling of euphoria and well-being in comparison to the two drugs alone. Expand
Effects of dextromethorphan on MDMA-induced serotonergic aberration in the brains of non-human primates using [123I]-ADAM/SPECT
TLDR
The results suggest that DM may exert a protective effect against MDMA-induced serotonergic toxicity in the brains of the non-human primate. Expand
Acute Pharmacological Effects of 2C-B in Humans: An Observational Study
TLDR
Oral 2C-B at recreational doses induces a constellation of psychedelic/psychostimulant-like effects similar to those associated with serotonin-acting drugs. Expand
...
1
2
...

References

SHOWING 1-10 OF 52 REFERENCES
Human pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) after repeated doses taken 2 h apart
TLDR
MDMA pharmacokinetics and metabolic disposition following two doses separated by 2 h show that the contribution of the first dose to the MDMA-induced mechanism-based metabolic inhibition was already apparent and the concentrations of MDMA after the second dose were slightly higher than expected. Expand
Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
TLDR
Pharmacological effects after the second administration of MDMA were higher than those following the first but lower than expected, and a disproportionate increase in plasma concentrations in MDMA and MDA was observed most likely due to metabolic inhibition. Expand
3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics.
TLDR
MDMA reversed the subjective sedation induced by alcohol but did not reduce drunkenness feelings, and the MDMA-alcohol combination induced longer lasting euphoria and well being than MDMA or alcohol alone. Expand
Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans.
The cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") were assessed in a double-blind, randomized, crossover, and controlledExpand
Pharmacological Interaction between 3,4-Methylenedioxymethamphetamine (Ecstasy) and Paroxetine: Pharmacological Effects and Pharmacokinetics
TLDR
It seems that paroxetine could interact with MDMA at pharmacodynamic (serotonin transporter) and pharmacokinetic (CYP2D6 metabolism) levels, whereas MDMA alone produced the prototypical effects of the drug. Expand
Sex Differences in 3,4-Methylenedioxymethamphetamine (MDMA; Ecstasy)-Induced Cytochrome P450 2D6 Inhibition in Humans
TLDR
This study assessed the inhibition and recovery half-life of CYP2D6 and CYP3A4 activity in female subjects by administering the probe drug dextromethorphan before and repeatedly after MDMA administration, and found an apparent decrease in a decrease in dextrochemical clearance. Expand
Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"): psychomotor performance and subjective effects.
TLDR
The short-term administration of MDMA produced marked euphoria, a slight impairment in the performance of psychomotor tasks, and mild changes in body perceptions without hallucinations, which support the abuse liability of MDMA. Expand
Non-linear pharmacokinetics of MDMA ('ecstasy') in humans.
TLDR
The lack of linearity of MDMA pharmacokinetics (in a window of doses compatible with its recreational use) is a more general phenomenon as it concerns the whole population independent of their CYP2D6 genotype. Expand
Tolerance to 3,4-methylenedioxymethamphetamine in rats exposed to single high-dose binges
TLDR
The results suggest that MDMA tolerance in humans may reflect 5-HT deficits which could contribute to further dose escalation, and that tolerance developed only in rats exposed to high-dose binges, hyperthermia and 5- HT depletion are implicated in this phenomenon. Expand
Effects of the α2-Adrenergic Agonist Clonidine on the Pharmacodynamics and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Healthy Volunteers
TLDR
The present findings do not support a role for α2-adrenergic receptor agonists in the prevention of psychostimulant dependence and indicate that vesicular release of norepinephrine, which is inhibited by clonidine, does not critically contribute to the effects of MDMA in humans. Expand
...
1
2
3
4
5
...